RxDoctor Payments DataLook up a doctor →

David Tran, MD

Internal Medicine · Covington, LANPI 1366419590

Payments from drug & device makers

$31,657in general payments, 2019–2025

Across 1,723 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$6K
  • AbbVie$4K
  • Novo Nordisk$3K
  • Lilly USA, LLC$2K
  • Amgen$1K
  • Pfizer$1K
  • plus $13K from 54 others

What the payments were for

  • Food & beverage$31,41899%
  • Education$2391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)168$5,819
AbbVie(2 entities)266$4,405
Novo Nordisk171$2,903
Lilly USA, LLC125$2,116
Amgen(2 entities)111$1,479
Pfizer99$1,410
Boehringer Ingelheim69$1,130
Axsome Therapeutics, Inc.58$1,037
Bayer50$928
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC65$876
Kowa Pharmaceuticals America, Inc.59$857
Lundbeck LLC43$725
Supernus Pharmaceuticals, Inc.25$684
GSK31$524
Astellas Pharma US Inc25$520
Merck33$515
Sanofi-aventis U.S. LLC27$458
Otsuka America Pharmaceutical, Inc.23$366
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$354
Biohaven Pharmaceuticals, Inc.9$353
Ironwood Pharmaceuticals, Inc20$301
Idorsia Pharmaceuticals US Inc18$300
Esperion Therapeutics, Inc.23$299
Takeda Pharmaceuticals U.S.A., Inc.20$270
Johnson & Johnson(2 entities)13$239
Antares Pharma, Inc.15$226
Harmony Biosciences LLC7$217
Sunovion Pharmaceuticals Inc.20$193
Amarin Pharma, Inc.9$192
Kyowa Kirin, Inc.8$150
Noven Therapeutics, LLC9$140
Upsher-smith Laboratories LLC8$130
Tolmar, Inc.6$116
Nevro Corp.2$113
Novartis6$101
Eisai Inc.5$95
Biogen5$90
Vertiflex, Inc.1$78
Nestle Healthcare Nutrition Inc.4$72
Stryker3$69
Abbott3$54
Corium, LLC4$48
Vertex2$43
E.r. Squibb & Sons, L.L.C.2$42
Assertio Therapeutics, Inc.2$38
Clarus Therapeutics Inc.2$36
Inspire Medical Systems, Inc.2$36
Tactile Systems Technology Inc2$36
Acerus Pharmaceuticals Corporation2$34
Halozyme Inc2$33
Biohaven Pharmaceutical Holding Company Ltd.2$33
Currax Pharmaceuticals LLC2$32
Tris Pharma Inc2$29
Jazz Pharmaceuticals Inc.2$29
Bioxcel Therapeutics, Inc.1$28
Intra-sana Laboratories1$26
Boston Scientific1$24
Dexcom, Inc.1$24
Kerecis Limited1$23
Shield Therapeutics Inc1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,657 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$375,239
Medicare patients
297
Services billed
3,966

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol310$315,229
MounjaroTirzepatide153$198,824
OzempicSemaglutide88$134,740
EliquisApixaban199$109,254
JardianceEmpagliflozin130$105,504
RexultiBrexpiprazole44$51,327
XifaxanRifaximin11$34,810
XareltoRivaroxaban34$34,405
VraylarCariprazine Hcl21$28,918
Tresiba Flextouch U-200Insulin Degludec31$28,187
LinzessLinaclotide32$18,970
EntrestoSacubitril/Valsartan18$17,260
TradjentaLinagliptin30$16,848
JanuviaSitagliptin Phosphate15$15,327
Breo ElliptaFluticasone/Vilanterol16$14,873

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$5,819$329,769343 claims
Lilly USA, LLCMounjaro$2,116$198,824153 claims
Novo NordiskOzempic$2,903$134,74088 claims
Boehringer IngelheimJardiance, Tradjenta$1,130$122,351160 claims
PfizerEliquis$1,410$109,254199 claims
Otsuka America Pharmaceutical, Inc.Rexulti$366$51,32744 claims
AbbVieVraylar, Linzess$4,405$47,88753 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$876$34,81011 claims
Johnson & JohnsonXarelto$239$34,40534 claims
GSKBreo Ellipta, Trelegy Ellipta$524$24,87532 claims
NovartisEntresto$101$17,26018 claims
MerckJanuvia$515$15,32715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Covington

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →